Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
· seekingalpha.com
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, 2026...
Presentation
Operator
Good afternoon, and welcome to the Candel Therapeutics conference call, where the company will be discussing extended follow-up data fro...